Relationship between Regulatory T Cells and the Combination of Pegylated Interferon and Ribavirin for the Treatment of Chronic Hepatitis Type C
Relationship between Regulatory T Cells and the Combination of Pegylated Interferon and Ribavirin for the Treatment of Chronic Hepatitis Type C
复制标题
DOI：
10.1159/000274976
复制
发表时间：
2010-01-01
期刊：
影响因子：
4.6
通讯作者：
Nakao, Kazuhiko
中科院分区：
文献类型：
--
作者：
Akiyama, Motohisa;Ichikawa, Tatuki;Nakao, Kazuhiko
背景/目的：调节性T细胞（TCRs）的频率可能与持续性丙型肝炎病毒（HCV）感染有关。我们研究了慢性丙型肝炎患者在联合治疗期间外周血单个核细胞（PBMC）中Treg比例的变化，并与治疗前肝脏浸润淋巴细胞（LILs）中Treg比例进行了比较。方法：研究组包括20例未经治疗的HCV基因1型高病毒滴度患者。在给药前和给药期间的几个时间点采集血样。所有患者在治疗前均接受肝活检。用特异性抗体对PBMC和LILs中的叉头盒P3（Foxp 3）+、CD 3+、CD 4+和CD 8+细胞进行染色。结果：10例患者有持续病毒学应答（SVR），10例患者无应答。SVR组在8周和12周时PBMC中Foxp 3 +/CD 4+比率显著增加，LILs中Foxp 3 +/CD 4+比率显著降低，CD 8 +/Foxp 3+比率增加。结论：治疗前LILs和治疗期间PBMC中的THBG（持续HCV感染的潜在重要因素）的评价可预测联合治疗的结果。版权所有（C）2010 S. Karger AG，巴塞尔
Background/Aim: The frequency of regulatory T cells (Tregs) may be related to persistent hepatitis C virus (HCV) infection. We studied the alteration of the Treg ratio in peripheral blood mononuclear cells (PBMCs) from chronic hepatitis C patients during combination therapy compared with the Treg ratio in liver-infiltrating lymphocytes (LILs) before therapy. Method: The study group consisted of 20 patients who were treatment-naive and had high virus titers of HCV genotype 1. Blood samples were collected prior to treatment and at several time points during treatment. All patients received a liver biopsy prior to treatment. Forkhead box P3 (Foxp3)+, CD3+, CD4+ and CD8+ cells in PBMCs and LILs were stained by specific antibodies. Results: Ten patients had a sustained virological response (SVR), and 10 patients were non-responders. The SVR group had a significant increase in the Foxp3+/CD4+ ratio in PBMCs at 8 and 12 weeks as well as a significant decrease in the Foxp3+/CD4+ ratio and increase in the CD8+/Foxp3+ ratio in LILs. Conclusion: The evaluation of Tregs, a potentially significant factor for persistent HCV infection, in LILs prior to treatment and in PBMCs during treatment could predict the result of combination therapy. Copyright (C) 2010 S. Karger AG, Basel